AN2 Therapeutics, Inc. Deferred Tax Assets, Goodwill and Intangible Assets
AN2 Therapeutics, Inc. (ANTX) had Deferred Tax Assets, Goodwill and Intangible Assets of $5.34 million as of 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Notes
us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets · last filed 2023-03-29
- 2022-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $5.34M.
| Period end | Deferred Tax Assets, Goodwill and Intangible Assets |
|---|---|
| 2022-12-31 | $5.34M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |